Implicating Calpain in Tau-Mediated Toxicity In Vivo by Reinecke, James B. et al.
Implicating Calpain in Tau-Mediated Toxicity In Vivo
James B. Reinecke
., Sarah L. DeVos
., James P. McGrath, Amanda M. Shepard, Dustin K. Goncharoff,
Don N. Tait, Samantha R. Fleming, Michael P. Vincent, Michelle L. Steinhilb*
Department of Biology, Central Michigan University, Mount Pleasant, Michigan, United States of America
Abstract
Alzheimer’s disease and other related neurodegenerative disorders known as tauopathies are characterized by the
accumulation of abnormally phosphorylated and aggregated forms of the microtubule-associated protein tau. Several
laboratories have identified a 17 kD proteolytic fragment of tau in degenerating neurons and in numerous cell culture
models that is generated by calpain cleavage and speculated to contribute to tau toxicity. In the current study, we
employed a Drosophila tauopathy model to investigate the importance of calpain-mediated tau proteolysis in contributing
to tau neurotoxicity in an animal model of human neurodegenerative disease. We found that mutations that disrupted
endogenous calpainA or calpainB activity in transgenic flies suppressed tau toxicity. Expression of a calpain-resistant form of
tau in Drosophila revealed that mutating the putative calpain cleavage sites that produce the 17 kD fragment was sufficient
to abrogate tau toxicity in vivo. Furthermore, we found significant toxicity in the fly retina associated with expression of only
the 17 kD tau fragment. Collectively, our data implicate calpain-mediated proteolysis of tau as an important pathway
mediating tau neurotoxicity in vivo.
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Introduction
Alzheimer’s disease (AD) belongs to a group of related neuro-
degenerative disorders known as tauopathies, whose common
pathological feature involves the deposition of abnormal, aggre-
gated, highly phosphorylated tau in neuronal cells. Hyperpho-
sphorylated tau is the major component of protein aggregates such
as paired helical filaments (PHFs) and neurofibrillary tangles
(NFTs) found in AD brain. Because mutations in the tau gene
locus cause familial neurodegeneration with neurofibrillary tangle
formation [1,2,3,4], it is clear that primary abnormalities in tau are
sufficient to cause neurodegeneration. However, the mechanisms
leading to tau-induced neuronal cell death still require further
definition.
In order to study the role of tau in disease, several animal model
systems have recently been developed. In 2001, Wittmann and
colleagues created a tauopathy model using the fruit fly Drosophila
melanogaster. Transgenic flies expressing wild-type and mutant
forms of human tau recapitulate many features of the human
disease including adult onset, progressive neurodegeneration, early
death, enhanced toxicity of mutant tau, and accumulation of
abnormal tau [5]. The tau-induced rough eye phenotype provides
an excellent model system to evaluate tau toxicity: genetic
modifiers and pharmacological agents are capable of enhancing
and suppressing the tau rough eye [6].
The role that kinases play in mediating neurodegeneration in
Alzheimer’s disease and related disorders has been a topic of
significant interest. One potential manner in which phosphoryla-
tion may affect tau toxicity is by influencing the susceptibility of
tau to proteolysis. Tau is known to be the target of several intra-
cellular proteases including caspases, cathepsins, the proteasome,
and calpain [7,8,9]. Importantly, tau fragments have recently been
reported to be released from degenerating cultured rat cortical
neurons, and small tau fragments are being assessed for their utility
as biomarkers in preclinical and clinical assessment of acute
neurodegenerative disorders [10]. The generation of a 17 kD tau
fragment has been reported in cerebellar granule cells undergoing
apoptosis [11] as well as hippocampal neurons exposed to
aggregated Ab [12,13]. The 17 kD fragment is likely generated
by calpain cleavage of tau and the 17 kD fragment itself is found to
be toxic when exogenously expressed in neuronal and non-
neuronal cells [12]. Most recently, Ferreira and Bigio [14]
reported elevated levels of the 17 kD tau fragment and enhanced
calpain activity in the brains of patients with AD and other
tauopathies. These data implicate calpain-mediated proteolysis of
tau as an important pathway mediating tau toxicity.
Calpain targets several proteins, including notably the structural
components of the cytoskeleton such as MAP-1, MAP-2, actin,
spectrin, and neurofilaments and has been shown to cleave tau
directly in PC12 cells [15,16]. In addition, calpain catalyzes the
p35Rp25 event that activates cyclin-dependent kinase 5 (cdk5), a
proline-dependent kinase implicated in tau hyperphosphorylation
in AD and other tauopathies [17]. Recently, calpain has been
shown to participate in processing of amyloid precursor protein by
increasing levels of BACE-1, leading to increased Ab production,
and ultimately elevated plaque load [18].
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found in organisms ranging from yeast to humans. In humans,
there are 2 types of calpain, classified based on the concentration
of calcium (Ca
2+) required to elicit enzymatic activity. Calpain I
(m-calpain) is activated at micromolar Ca
2+ concentrations and is
the major form expressed in neuronal cells. Calpain II (m-calpain)
is active when cellular Ca
2+ concentrations are in the millimolar
range [19]. Although mammals possess at least 14 calpain genes,
Drosophila has only four (CalpainA-D) and only calpA and calpB
are predicted to have enzymatic activity [20].
In addition to Alzheimer’s disease, calpain has been implicated
in the pathogenesis of other neurodegenerative diseases. Hunting-
ton’s disease is caused by a polyglutamine (polyQ) tract expansion
near the amino-terminus of the protein huntingtin. Mutation of
two calpain cleavage sites in huntingtin renders the polyQ
expansion less susceptible to proteolysis and aggregation, resulting
in decreased toxicity in a cell culture model. In addition, a number
of calpain family members appear to be increased and activated in
Huntington’s disease tissue culture and transgenic mouse models
[21,22]. A recent report examining proteolytic processing and
disease-linked aggregation in Parkinson’s disease found that
calpain cleaves a-synuclein, leading to the formation of aggregated
high-molecular weight species and adoption of b-sheet structure
[23]. Dufty and colleagues detected calpain-cleaved a-synuclein in
mouse and fly models of Parkinson’s disease, as well as in the
substantia nigra of human Parkinson’s disease brain tissue.
Recently,therehasbeena significantincreaseinthedevelopment
of cell culture model systems to study tau toxicity. In culture, the
greatest challenge has been finding a cell line and isoform of tau that
recapitulates the clinical features of tau in human disease, including
aggregation, hyperphosphorylation and proteolytic degradation.
Several useful cell models now exist using various strategies for
evaluating tau toxicity. Canu et al. has effectively demonstrated the
use of cerebellar granule cells undergoing apoptosis to study the
effect of cell death on tau and microtubules [11]. SH-SY5Y
neuroblastoma cells stably over-expressing tau have been used to
evaluate tau phosphorylation and proteolytic degradation [8,24].
To study the generation of 17kD tau proteolytic fragments, other
groups have treated rat hippocampal neurons with pre-aggregated
Ab [12,13,14]. Inducible expression of the repeat domain of tau in
theneuroblastomacellline N2arecapitulatesrobusttauaggregation
and formation of Alzheimer’s-like paired helical filaments [25,26].
In non-neuronal cell culture, human epithelial kidney (HEK293)
cells expressing full-length tau have been treated with Congo red (a
small-molecule agonist of tau aggregation) to study tau aggregation
and the importanceof phosphorylation[27]. Full-lengthtau and tau
fragments have been expressed in Chinese hamster ovary (CHO)
cells [12,28]. These models set a precedent for the effective use of
cell culture models to study tau toxicity.
Because the appearance of truncated tau fragments has
profound significance in human disease, it is important to
understand the effect of tau proteolysis not only in cell culture,
but also in an intact animal system. The tauopathy model in
Drosophila offers a unique system to analyze the role of calpain in
tau-induced neurotoxicity: using the powerful genetic and
molecular tools available in flies, we can assess the pathological
importance of calpain cleavage of tau in an intact animal model of
human neurodegenerative disease.
Results
Tau and Calpain Colocalize in Drosophila Neurons
Since we hypothesized that calpain cleavage of tau may be an
important event in tau toxicity, we sought to determine whether
tau and calpain possess overlapping localization in neurons.
Although there are at least 14 human calpain-like protease
domain-containing genes, flies have only four (calpA-D). Only
calpA and calpB are predicted to have enzymatic activity. CalpC
has been speculated to be the Drosophila equivalent of calpastatin,
the endogenous mammalian inhibitor of calpain and calpD
(originally called SOL for small optic lobe) is an atypical member
of the calpain family that does not possess protease activity
[20,29]. As a consequence, we focused specifically on calpA and
calpB.
To determine the subcellular localization of tau and calpain in
Drosophila neurons, we used the elav-GAL4 driver to express human
tau (tau
WT) in all post-mitotic neurons. Neurons were isolated
from elav; tau
WT third instar larvae/white pre-pupae and stained
for human tau and endogenous fly calpains. As shown in Figure 1,
tau displayed perinuclear staining with some staining shown in the
processes radiating out from the cell body (panels A and D). CalpA
appears to be ubiquitously expressed throughout the cell body and
projections (panel B) while calpB expression was primarily
localized to the soma in a perinuclear pattern (panel E). Both
calpA and calpB showed colocalization with tau (panels C and E),
with the site of greatest overlapping subcellular distribution in the
cell body.
Because calpA and calpB are calcium-activated proteases, we
tested whether stimulation with ionomycin impacted the coloca-
lization of tau with calpain. We found no difference in localization
between ionomycin-treated and untreated neurons (data not
shown).
Calpain Mutants Suppress Tau-induced Toxicity in the Fly
Eye
In order to assess the pathological significance of calpain
cleavage of tau in an intact animal, we utilized a Drosophila
tauopathy model. This model is particularly attractive as the rough
eye phenotype of human tau-expressing flies can be enhanced and
suppressed by genetic modifiers [6]. We genetically modulated
calpain in flies using mutant alleles of endogenous Drosophila
calpain to decrease expression levels. For both calpA and calpB we
selected one deficiency line and two P-element insertion lines for
analysis.
Figure 1. Colocalization of tau and calpain in Drosophila
neurons. Neuronal cells cultured from late 3
rd instar larvae expressing
tau
WT were stained for tau in red (A and D), calpain A and calpain B in
green (B and E, respectively), with colocalization shown in yellow (C and
F). The expression pattern of calpain A and B was similar to that of tau,
with the primary site of colocalization in the neuronal cell body. Scale
bar =5 mM.
doi:10.1371/journal.pone.0023865.g001
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transgenic flies (Figure 2A) and flies possessing only the retinal
driver GMR-GAL4 (Figure 2B) possess an ordered ommatidial
morphology characterized by a regular array of bristles and lenses.
Expression of tau
WT in the retina caused a moderate rough eye
phenotype characterized by disruption of the ordered ommatidial
arrangement and a moderate reduction in the size of the eye
(Figure 2C). Compared to tau
WT-expressing flies, transgenic flies
expressing tau
WT together with calpA
6866, calpA
1545, or calpA
13868
had reduced tau toxicity as shown by suppression of the rough eye
phenotype (Figure 2D–F). Tau toxicity was also modestly reduced
in flies expressing tau
WT together with any of the calpB-reducing
alleles calpB
997, calpB
17422 or calpB
4062 (Figure 2G–I). Collective-
ly, these results suggest that genetically reducing calpA or calpB is
sufficient to suppress tau toxicity in vivo.
Having found that transgenic flies with mutations predicted to
disrupt endogenous calpA or calpB suppressed tau toxicity, we
verified that these flies indeed had reduced levels of calpain
expression and calpain activity. As shown in Figure 3, quantitative
western blot analysis confirmed that calpain expression levels were
significantly reduced in all of the calpA and calpB mutants used.
Compared to tau
WT, calpain levels were reduced in the six calpain
mutants by 20–45%. Importantly, tau expression levels in the
calpain mutant lines were the same as in tau
WT-expressing flies.
Using a fluorogenic calpain activity assay, we also found that
calpain activity was reduced in all of the calpA and calpB mutants
tested.
Creation of Tau
CR and Tau
17kD
Based on antibody analysis by other researchers [11,30] and the
predicted calpain cleavage sites in tau [31,32], the reputed toxic
17 kD tau fragment is likely to include amino acids 45–230.
Calpain favors cleavage at methionine, alanine, arginine, or lysine
preceded by leucine or phenylalanine [31,32]. Full-length human
tau contains 9 putative calpain cleavage sites: Met11, Lys44,
Arg230, Lys254, Lys257, Lys267, Tyr310, Lys340, and Tyr 394
(17 kD fragment start/end shown in bold; see Figure 4) [30]. To
determine whether inhibiting calpain cleavage of tau could modify
neurotoxicity, we generated a calpain-resistant tau construct
(tau
CR) for expression in Drosophila in which calpain cleavage sites
at K44 and R230 were mutated to glutamine (Q) using site-
directed mutagenesis (tau-K44Q/R230Q; see Figure 4). Gluta-
mine was chosen as a substitution since it is structurally similar to
lysine and arginine but it no longer has a charged polar side chain.
Since research from other laboratories suggested that the 17 kD
fragment of tau has intrinsic toxicity in neuronal and non-neuronal
cell types [12,33,34,35], we used PCR to create an additional tau
mutant (tau
17kD) in which only the amino acids corresponding to
the reputed toxic 17 kD fragment (aa 44–230) were expressed in
Drosophila (Figure 4).
We used western blot analysis to assess tau expression levels in
our new tau
CR and tau
17kD transgenic lines. As shown in
Figure 5A, tau expression levels are identical in tau
WT- and
tau
CR-expressing flies. Interestingly, expression of the 17 kD
fragment in flies was more challenging. We received only five
transgenic lines from the injection service we contracted and the
lines we recovered expressed low amounts of 17 kD tau. Initial
analyses with these five lines showed that when expressed with
GMR-GAL4 at 25uC, there was no detectible modification of the
non-transgenic eye phenotype and concurrently, we were unable
to detect tau expression in these flies. To enhance expression of the
17 kD fragment, we set-up crosses with tau
17kD- and tau
WT-
expressing flies reared at 31uC. We found that with equivalent
protein loading, tau
17kD-expressing flies produce a 17 kD form of
tau that was recognized by the Tau-1 antibody (Figure 5B). We
found that the 17 kD tau fragment was lower in abundance than
full-length tau
WT in Drosophila. However, given that the reputed
toxic 17 kD fragment is a cleavage product of tau, we did not bias
ourselves in thinking that expression levels of tau
17kD should be
equivalent to that of tau
WT. Since tau
17kD flies do not possess the
full-length human tau transgene, as expected, we did not see full-
length tau in these flies.
To determine whether the proteins generated by our tau
CR- and
tau
17kD-expressing flies were phosphorylated in vivo, we performed
a phosphatase assay. As shown in Figure 5C, phosphatase
treatment reduced the molecular weight of both wild-type and
calpain-resistant tau, but did not influence the mobility of the
17 kD tau fragment. The mobility shift observed with phosphatase
treatment supports that tau
CR is synthesized as a full-length
protein and is indeed phosphorylated to the same extent as tau
WT
in vivo. The resistance of the 17 kD fragment to phosphatase
Figure 2. Calpain mutants suppress tau-induced toxicity in the
fly eye. As shown using scanning electron microscopy, compared to
the normal external appearance of control flies (w
1118 in A; GMR-GAL4/+
in B), flies expressing wild-type human tau (tau
WT; C) displayed the
moderately rough eye phenotype characterisitc of tau toxicity. Genetic
disruption of calpain A (D–F) or calpain B (G–I) using either deficiency
lines (D and G) or P-element insertions (E–F and H–I) effectively
suppressed tau toxicity.
doi:10.1371/journal.pone.0023865.g002
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ylated at sites that contribute significantly to a gel mobility shift.
Tau
CR and Tau
17kD Significantly Modify Tau Toxicity in
vivo
To determine if preventing cleavage of tau at the putative
calpain cleavage sites of K44 and R230 reduced the neurotoxicity
of tau in an intact animal model, we assessed expression of tau
WT
and tau
CR in the Drosophila retina using the GMR-GAL4 driver. As
shown in Figure 5D, compared to the rough eye phenotype seen in
tau
WT-expressing flies, tau
CR-expressing flies have markedly
reduced tau toxicity. In fact, the reduction in toxicity is so
significant that aside from a slight bristle defect, these flies are
nearly indistinguishable from non-transgenic flies. Thus, mutation
of K44 and R230 was sufficient to abrogate tau neurotoxicity in
vivo.
To establish whether expression of the 17 kD fragment of tau
was toxic in an intact animal model, we used the GMR-GAL4
driver to direct expression of the reputed toxic tau fragment in the
fly eye. At 31uC, tau
17kD-expressing flies possessed a rough eye
phenotype with equivalent toxicity compared to tau
WT-expressing
Figure 3. Calpain protein expression level and enzyme activity are decreased in calpain mutants. A. Using antibodies specific to calpain
A or calpain B, western blot analysis showed that compared to tau
WT-expressing flies, all of the calpain mutant lines have lower levels of calpain
expression (top). Tau expression levels for all of the calpain mutants are equivalent to the expression level of tau in tau
WT-expressing flies using both
Tau 5 and Tau-1 antibodies (bottom two panels). B. When normalized to the level of calpain in tau
WT-expressing flies, densitometric analysis revealed
reduced calpain expression in all calpain mutant lines tested (top). The values shown represent the mean of three or more independent experiments.
When normalized to calpain activity in tau
WT-expressing flies, all calpA and calpB mutants have reduced calpain activity (bottom). The values shown
represent the mean of enzyme activity measured in triplicate. Error bars for both graphs represent the standard error of the mean and data points
indicated with asterisks are significant. *P,0.05, **P,0.01 (unpaired student t-test).
doi:10.1371/journal.pone.0023865.g003
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toxicity in tau
WT- and tau
17kD-expressing flies despite much lower
levels of 17 kD expression (see Figure 5B), these results are
consistent with substantially increased toxicity of the 17 kD
fragment of tau. Collectively, these results supported our
hypothesis that calpain is involved tau-mediated toxicity in vivo.
Discussion
Calpain proteolysis is emerging as an important mediator of
neurodegenerative disease. Recently, calpain has been implicated
in the production of toxic fragments in two other diseases besides
Alzheimer’s disease: a-synuclein in Parkinson’s disease [23] and
huntingtin in Huntington’s Disease [21,22,36]. All share a
common theme: calpain-cleaved, truncated forms of tau, a-
synuclein, and huntingtin have pathologic significance in their
respective diseases. It is therefore of the utmost importance to
understand at the molecular level the relationship between calpain
and the generation of toxic protein fragments. We are in a unique
position to study calpain cleavage of tau using an intact animal
model of human neurodegenerative disease, the Drosophila
tauopathy model.
In humans, calpain activity increases during normal aging,
however individuals with familial AD and other tauopathies have
significantly elevated levels of active calpain [37,38] as well as the
17 kD fragment of tau [14]. Activated calpain is detected prior to
tau abnormalities and neuronal cell death, suggesting that calpain
activation is not a consequence of the neurodegenerative process,
but rather precedes and promotes neurodegeneration [19]. One
study in particular found that the active form of calpain was
present together with hyperphosphorylated tau in 50–75% of
preparations from several human disorders, including tau
pathology associated with Alzheimer’s disease, Down’s syndrome,
diffuse Lewy body disease, progressive supranuclear palsy, and
corticobasal degeneration [37]. To test whether tau and calpain
exist in the same subcellular compartment in neuronal cells in our
model system, we prepared primary cultures of Drosophila neurons
for confocal analysis. As shown in Figure 1, human tau colocalizes
with both calpA and calpB in Drosophila neurons. This places tau
and calpain in close proximity to execute the cleavage event to
produce potentially toxic tau fragments in our model. Our
observation was consistent with other reports that find activated
calpain in association with hyperphosphorylated tau [37,39].
Having first established that tau and calpain colocalize in the
Drosophila nervous system, we examined whether altering calpain
expression genetically could modify the tau-induced rough eye
phenotype observed in the Drosophila tauopathy model. We
hypothesized that if calpain plays a role in eliciting tau toxicity,
genetically decreasing the amount of calpain in flies may suppress
tau toxicity. Using fly stocks available from public stock centers we
found exactly this result: calpain mutant lines that function to
decrease physiological levels of calpain suppressed the tau rough
eye phenotype in vivo (Figure 2). Western blot analysis confirmed
that the suppression of the tau-induced rough eye was not a
consequence of modifying tau levels in these flies since tau
expression levels found in fly head homogenates were unchanged
compared to flies expressing only tau
WT. Compared to tau
WT-
expressing flies, calpain expression levels, however, were signifi-
cantly reduced in homogenates from flies expressing any of the
calpA or calpB mutants together with tau
WT (see Figure 3). In
addition to assessing calpain expression levels by western blot, we
employed quantitative RT-PCR as a secondary measurement of
calpain expression level and found .2 fold reduction in calpA
mRNA in the calpA mutants compared to tau
WT and .1.1 fold
reduction in calpB mutants (data not shown). Using a fluorogenic
calpain activity assay, we observed decreased calpain activity in all
of the calpA and calpB mutants. Although we found a 20-45%
decrease in calpain expression levels, we observed a #10%
reduction in calpain activity. It is important to note that while the
quantitative protein expression data were generated using
antibodies that recognize only calpA or calpB, the calpain activity
assay measures the contribution of both calpA and calpB to total
enzyme activity. Since the genetic reduction of either calpA or
calpB affects only one of the two functional calpain genes, it is not
surprising that the reduction in calpain expression level is not
identical to the overall reduction in calpain enzymatic activity.
Given that tau toxicity is suppressed under conditions where
calpain levels are genetically reduced, we are currently making
calpain over-expressing transgenic lines to test whether elevated
levels of calpain enhance tau toxicity.
Inhibiting calpain pharmacologically or with overexpression of
calpastatin (the endogenous inhibitor of calpain) has been
documented to impact tau proteolysis [11,18,40,41,42] or reduce
neuronal death [43,44]. Using the calpain inhibitor MDL 28,170,
we established a dose-response curve and found the optimum drug
concentration for our feeding experiments to be 1 mM. However,
upon drug administration we found no effect of MDL 28,170 on
tau toxicity (data not shown).
Although compelling, the modifier analysis does not distinguish
whether the impact of calpain upon tau is direct or indirect. Since
calpain is involved with activation of cdk5, a major tau kinase,
several laboratories have suggested that the role of calpain in
Figure 4. Cleavage of tau by calpain creates the 17 kD
fragment. A. Schematic of 0N4R tau with the nine putative calpain
cleave sites indicated. Proteolysis at lysine 44 (K44) and arginine 230
(R230) yields a 17 kD fragment of tau. Abbreviations: methionine (M),
lysine (K), arginine (R), and tyrosine (Y). B. The K44Q/R230Q mutation is
predicted to disrupt the recognition motif for calpain at K44 and R230
and thus creates a calpain-resistant (tau
CR) form of tau for expression in
Drosophila. PCR was used to create a second tau mutant (tau
17kD)i n
which only the amino acids corresponding to the reputed toxic 17 kD
fragment (aa 44-230) are expressed in Drosophila.
doi:10.1371/journal.pone.0023865.g004
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causing cytoskeletal disruption and neuronal apoptosis [17,45,46].
Other researchers postulate that as a protease, calpain interacts
with hyperphosphorylated tau in an effort to degrade the protein
to avoid cellular toxicity [13,14,47]. To determine whether calpain
promotes tau toxicity by cleaving tau directly, we made specific
mutations to alter the putative calpain cleavage sites on tau that
are predicted to produce the toxic 17 kD fragment. Significant
effort has been made to discern the amino acid consensus
sequence for calpain cleavage of target proteins. Given the wide
range of calpain targets, no single consensus sequence motif has
prevailed. Rather, higher-order structural features such as peptide
bond accessibility, backbone conformation, and three-dimensional
structure were found to be important. In general however, calpain
favors cleavage at methionine, alanine, arginine, or lysine
preceded by leucine or phenylalanine [31,32]. As shown in
Figure 4A, tau contains 9 putative calpain cleavage sites [30].
Analysis of the 17 kD tau fragment using sequence-specific
monoclonal antibodies suggests that that lysine 44 (K44) and
arginine 230 (R230) define the boundaries of the fragment
generated by calpain cleavage that correlates with toxicity
[11,12]. Since the interaction of the P1 residue of a substrate
with the S1 subsite of the enzyme is critical for substrate
orientation leading to efficient catalysis, we elected to mutate the
P1 residues at the two critical calpain cleavage sites, namely K44
and R230. Glutamine was selected as a substitution for K44 and
R230 since it is structurally most similar to lysine and arginine but
it no longer has a charged polar side chain. As shown in Figure 5,
with equivalent protein expression levels, mutation of only two
amino acids in tau at the predicted sites of calpain cleavage was
sufficient to abrogate tau toxicity in vivo.
At least two other groups have attempted to block production of
the 17 kD fragment using site-directed mutagenesis at the
predicted calpain cleavage sites of tau using the P2-P1 rule [32],
which predicts the preferred residues surrounding the scissile bond
for calpain cleavage of target proteins [12,28]. While Park and
Ferreira found that L43A/V229A prevented the appearance of
the 17 kD fragment, Garg et al. found that neither L43A alone nor
L43A together with V229A prevented generation of the 17 kD
fragment of tau. While our results are consistent with Park and
Ferreira whose experiments utilized cultured neurons, we
speculate that the different results obtained by Garg and
colleagues may be due, at least in part, to the fact that their
experiments were performed on constructs expressed in non-
neuronal Chinese Hamster Ovary (CHO) cells using recombinant
calpain 2.
The generation of a 17 kD tau fragment has been reported in
cerebellar granule cells undergoing apoptosis [11,47,48] and
hippocampal neurons exposed to aggregated Ab [12,13,33,35],
and was found to be toxic when exogenously expressed in
neuronal and non-neuronal cells [12]. Most recently, Ferreira and
Bigio [14] reported increased levels of the 17 kD tau fragment and
elevated calpain activity in brain samples from patients with
Figure 5. Modifying two putative calpain cleavage sites in tau
significantly impacts tau toxicity in vivo. A. Western blot analysis
of fly head homogenates revealed equivalent tau expression levels in
tau
CR-expressing flies compared to tau
WT-expressing flies. There is no
cross-reactivity of the Tau-1 or Tau 5 antibody with homogenates from
control flies (GMR/+). B. Expression of the 17 kD fragment could not be
detected at 25uC and instead required crosses to be conducted at 31uC.
Possessing only the coding sequence for amino acids 44-230, tau
17kD-
expressing flies made only a ,17 kD tau fragment that is found at
lower abundance than that of full-length tau found in tau
WT–expressing
fly head homogenates with equivalent protein loading. C. Treatment of
fly head homogenates from tau
WT-, tau
CR- and tau
17kD-expressing flies
with lambda phosphatase indicated that both the wild-type and
calpain-resistant forms of tau experienced a mobility shift with
phosphatase treatment whereas the 17 kD fragment was resistant to
phosphatase treatment. To ensure we would visualize a potential
molecular weight shift of the 17 kD fragment by western blot, the
phosphatase assay employed three times more fly head homogenate
from tau
17kD-expressing flies than tau
WT or tau
CR flies. D. When
compared to the rough eye phenotype in tau
WT-expressing flies, tau
CR
flies demonstrated no detectable tau toxicity. E. At 31uC, transgenic flies
that express only the 17 kD tau fragment (tau
17kD) showed equivalent
or slightly enhanced tau toxicity compared to the toxicity associated
with expressing tau
WT in the retina, suggesting that the 17 kD fragment
possesses intrinsic toxicity in vivo. Control flies in D and E are GMR/+.
doi:10.1371/journal.pone.0023865.g005
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toxicity of the 17 kD fragment can be extended beyond cell culture
models to establish whether the 17 kD tau fragment elicited
toxicity in an intact animal system as well. We found that the
17 kD fragment possessed intrinsic toxicity in vivo since expression
of even modest levels of the 17 kD fragment resulted in substantial
toxicity in the fly retina (Figure 5E).
In Drosophila, several molecular pathways have been implicated
in tau neurotoxicity and influence neurotoxicity in the fly eye at
different times in development. While the unfolded protein
response protects against tau neurotoxicity [49], lysosomal
dysfunction [50,51], abnormal bundling and accumulation of F-
actin [52] and other cytoskeletal proteins [53,54], oxidative stress
[55], and tau phosphorylation [56,57,58,59] are among the
pathways shown to promote tau neurotoxicity in vivo. With respect
to the rough eye phenotype in tau
17kD-expressing flies, we are not
certain of the mechanism controlling the tau-induced neurotox-
icity we observe.
We have been largely unsuccessful at visualizing the 17 kD
fragment in tau
WT-expressing Drosophila lines unless we are
specifically expressing this fragment using our tau
17kD transgenic
lines. Although we have visualized a very faint band corresponding
to the 17 kD fragment in tau
WT-expressing flies (unpublished
observation), these experiments typically require homogenates
prepared with .300 fly heads and the appearance of the 17 kD
fragment is sporadic and typically at the very limit of detection
using western blot analysis. We suspect that the 17 kD fragment
may be quickly degraded in flies and therefore its presence is
particularly difficult to monitor. Consistent with this finding,
others using in vitro calpain cleavage assays can only detect the
17 kD fragment when tau is in a soluble form [14]. Given that in
the fly tauopathy model, the altered conformation and hyperpho-
sphorylated state of tau correlates with tau toxicity in the absence
of neurofibrillary tangle formation [5], it is possible that the
structure and/or phosphorylation status of tau may be important
for generating the 17 kD fragment.
Several studies have suggested that the primed sites of substrates
(i.e. amino acids C-terminal to the scissile bond) are significantly
involved in peptide recognition and the kinetics of cleavage by
calpain [31,32,60]. In an extensive search for calpain substrates
within the Swiss-Prot and TrEMBL protein databases, Tompa et
al. reported that the frequency of the (S/T)P dipeptide in the P1’-
P2’ position was discovered with a surprisingly high frequency (5–
10X above average) among calpain substrates [32]. Interestingly,
threonine
231 (T
231) and proline
232 (P
232) occupy the P1’-P2’
position at the putative R
230 calpain cleavage site of tau. T
231 is
among a group of 14 SP/TP motifs present in tau and has been
shown to be hyperphosphorylated in Alzheimer’s disease and
other tauopathies [61,62][57]. Phosphorylation at T
231 (together
with S
235) creates the TG3 disease-associated phosphoepitope, a
site phosphorylated by several kinases including cdk5, a proline-
directed kinase that is activated by conversion of p35Rp25 by
calpain [17]. The presence of T
231P
232 at the P1’-P2’ position
would support a potential mechanism in which phosphorylation
regulates the susceptibility of tau to calpain cleavage and the
generation of potentially toxic proteolytic fragments.
Materials and Methods
Constructs, Genetics, and Stocks
All crosses were performed on standard cornmeal based
medium. Fly stocks UAS-tau
WT, GMR-GAL4 and elev-GAL4
were provided by Dr. Mel Feany and have been described
previously [5,57]. The following transgenic strains are described in
Flybase (http://flybase.bio.indiana.edu/) and were purchased
from Bloomington (http://fly.bio.indiana.edu/) or Exelixis
(https://
drosophila.med.harvard. edu/): CalpA
6866 (Df(2R)BSC26,
Bloomington); CalpA
1545 (pBac{RB}CalpA[e01545], Exelixis);
CalpA
13868 (P{SUPorP}KG05080, Bloomington); CalpB
997
(Df(3L)AC1, Bloomington); CalpB
17422 (P{EPgy2}Calp-
B[EY17422], Bloomington); CalpB
4062 (PBac{PB}CalpB[4062],
Exelixis). Vector pBS-htau24 (Wittmann 2001) served as the
template for generation of both calpain-resistant tau (tau
CR; tau-
K44Q/R230Q) and the 17kD fragment of tau (tau
17kD; tau
44-230)
using the QuikChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA). For tau
CR the forward primer for K44Q was
59CGGACGCTGGCCTGCAAGCTGAAG-AAGCAGG 39 and
the reverse primers was 59 CCTGCTTCTTCAGCTTGCAGG-
CCAG-CGTCCG 39. pBS-htau
K44Q was used as the template for
the R230Q mutation to make tau
K44Q/R230Q using the forward
primer 59 GGTGGCAGTGGTCCAGACTCCACCCAA-GTC-
G3 9 and the reverse primer 59 CGACTTGGGTGGAGTCTG-
GACCACTGCCACC 39. For tau
17kD the forward primer was 59
GATCGCGGCCGCATGAAAGCTGAAGAAGCAGGC 39 and
the reverse primer was 59 GATCCTCGAGTCACAGATCCTC-
TTCTGAGATGAGTTTTTGTTCA-CGGACCACTGCCAC-
CT 39. The tau
CR and tau
17kD constructs were subcloned into the
pUAST vector and sequenced to verify the authenticity of each
mutant. Mapped and balanced lines were created using the
Drosophila embryo injection services of The Best Gene, Inc. (Chino
Hills, CA). For both tau
CR and tau
17kD, we analyzed 5–8 mapped
and balanced transgenic lines and used quantitative western blot
analysis to determine protein expression level.
Drosophila Primary Cell Culture
Primary neurons were derived as described previously [63].
Briefly, CNS from surface sterilized (1 minute in 70% ethanol) late
wandering third instar larvae, pre-pupae (0–5 hours), or 50%
pupae were dissected in sterile calcium free buffer (800 mg NaCl,
20 mg KCl, 5 mg NaH2PO4, 100 mg NaHCO3, and 100 mg
glucose in 100 mL of culture grade water). Dissected brains were
placed in a solution containing 0.2 mg/mL collagenase (Type I,
Sigma, St. Louis, MO) diluted in calcium free buffer for 30
minutes at room temperature. CNS were washed three times for 5
minutes in plating medium (Schneider 2 media (Invitrogen,
Carlsbad, CA) plus 50 mg/mL insulin (Sigma) and 10% heat-
inactivated normal bovine serum (Rockland Immunochemicals,
Philadelphia, PA)). CNS were dispersed into single cells by
repeated passage through a pipet tip (,40 times) and plated
(100 mL) onto UV-sterilized circular coverslips (Electron Micros-
copy Sciences, Hatfield, PA) that had been coated with 167 mg/
mL concanavalin A (Sigma) and 1.67 mg/mL mouse-laminin
(Invitrogen) for 2 hours at 37uC. Cells were allowed to attach to
the coverslips for approximately 2–3 hours at 25uC before
additional plating medium was added. Cells were grown at 25uC
for 1–3 days prior to processing.
Immunohistochemistry
For immunofluorescence studies of primary neurons, plating
medium was removed and cells were rinsed two times in
phosphate-buffered saline (PBS; Denville Scientific, Metuchen,
NJ) followed by fixation in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA)/PBS for 10 minutes at room
temperature. After three washes in PBS plus 0.3% Triton-X 100
(PBT), cells were blocked for 30 minutes at room temperature in
PBT plus 0.2% bovine serum albumin (HyClone, Logan, UT) and
5% normal goat serum (PBTB; Rockland Immunochemicals).
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antibody overnight at 4uC: rat a-elav (1:100; Developmental
Studies Hybridoma Bank (DSHB, Iowa City, IA)), mouse a-22C10
(1:20, DHSB), mouse a-Tau-5 (1:100; DHSB), rabbit a-Calpain A
(1:1000; Friedrich and Farkas), and rabbit a-Calpain B (1:1000;
Friedrich and Farkas). Following primary antibody incubation,
samples were washed three times (10 minutes) in PBT followed by
incubation with the appropriate fluoro-conjugated secondary
antibody (1:200; Jackson ImmunoResearch, West Grove, PA) for
one hour at room temperature. After three washes in PBT, the
cells were mounted in Prolong Gold (Invitrogen) and visualized on
an Olympus FluoView 300 Confocal Microscope with a 60X oil
immersion lens at a 3x confocal zoom. z-stacks were made from
three 0.5 mm slices.
Scanning Electron Microscopy
Adult flies were fixed in 4% glutaraldehyde (Electron Micros-
copy Services) for $24 hours, dehydrated through a graded series
of ethanol solutions, critically point dried (Polaron critical point
dryer), and sputter coated (Denton Desk II sputter coater). Flies
were imaged using a JEOL JSM-840A Scanning Electron
Microscope.
Protein Isolation, SDS-PAGE, Western Blot
Fly head homogenates were prepared in Laemmli buffer
(Sigma) from adult flies 1-day post eclosion. Protein samples were
boiled for 5 minutes, centrifuged for 5 minutes at 13,000xg to
remove insoluble debris, and resolved by Sodium Dodecyl Sulfate
Polyacrylamide Electrophoresis (SDS-PAGE) using 12% separat-
ing gels (Bio-Rad, Hercules, CA). Proteins were transferred to
activated PVDF (Millipore, Billerica, MA), blocked in 5% milk in
phosphate buffered saline (Denville Scientific) with 0.1% Tween-
20 (Fisher Scientific, Pittsburg, PA), and incubated with one of the
following primary antibodies at 4uC overnight: rabbit a-calpain A
(1:10,000; Friedrich and Farkas), rabbit a-calpain B (1:10,000;
Friedrich and Farkas), Tau 5 (1:1000; Developmental Studies
Hybridoma Bank) or mouse a-Tau1 (1:5,000; Millipore). Mem-
branes were washed with PBST prior to incubation with the
appropriate a-mouse or a-rabbit horseradish peroxidase (HRP)
conjugated secondary antibody (1:10,000) followed by chemilu-
minescent signal detection with the SuperSignal West Pico
Detection Kit (Pierce, Rockford, IL). The Kodak GelLogic 2200
was used for digital image capture and densitometry analysis.
Statistical analysis was performed using the student t-test with
densitometry data from $3 separate experiments.
Phosphatase Assay
Phosphatase treatment was performed as described previously
[57]. Fly head homogenates from transgenic lines expressing
tau
WT, tau
CR and tau
17kD were prepared in 1X lambda
phosphatase buffer (New England Biolabs, Beverly, MA) contain-
ing a protease inhibitor cocktail (Roche, Indianapolis, IN). To
enhance visualization of the 17 kD fragment, homogenates for
tau
17kD contained three times more total protein than tau
WT or
tau
CR. Phosphatase-treated samples were incubated with lambda
protein phosphatase at 37uC for 3 hours. After the addition of
Laemmli buffer (Sigma), homogenates were subjected to SDS-
PAGE and western blot analysis as described above.
Calpain Activity Assay
Calpain activity was measured using a fluorogenic activity assay
kit following the protocol provided by the manufacturer (EMD
Chemicals, Inc., Gibbstown, NJ) with some modifications. Briefly,
fly head homogenates were prepared in CytoBuster Protein
Extraction Reagent (EMD Chemicals, Inc.) from adult flies 1-day
post eclosion, centrifuged for 1 minute at 13,000xg to remove
insoluble debris, and incubated with the substrate ((DABCYL)-
TPLKSPPPSPR-(EDANS)) in activation buffer with reducing
agent for 30 minutes at room temperature in the dark.
Fluorescence was measured using an excitation wavelength of
320 nm and an emission wavelength of 460 nm using a
fluorescence plate reader. Protein concentration was determined
using a Bradford-based microassay procedure (Bio-Rad). Statistical
analysis was performed using the student t-test with samples run in
triplicate.
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